Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 6/2014

01-06-2014 | Short Communication

Efficacy of adalimumab therapy for life-threatening pulmonary vasculitis in Behçet’s disease

Authors: Suhail Aamar, Hagit Peleg, David Leibowitz, Tova Chajek-Shaul, Nurith Hiller, Samuel N. Heyman

Published in: Rheumatology International | Issue 6/2014

Login to get access

Abstract

Inflammatory large-vessel vasculitis in Behçet’s disease may cause life-threatening arterial aneurysms that are prone to rupture. We report a patient with Behçet’s disease with right ventricular thrombus and large aneurysms of the pulmonary arteries that led to recurrent episodes of hemoptysis. Following relapses and only partial response to repeated courses of cyclophosphamide and steroids, the patient was treated with adalimumab (Humira) and is now in clinical remission for over 30 months, with regression of her pulmonary lesions. Anti-TNFα treatment is a potential therapeutic option in patients with life-threatening complications due to large-vessel vasculitis.
Literature
1.
Planer D, Leibowitz D, Elitzur Y, Korach A, Hiller N, Chajek-Shaul T (2007) Chronicle of a death foretold: a case of catastrophic vascular Behcet’s disease. Clin Rheumatol 26:457–459PubMedCrossRef
2.
Sfikakis PP (2002) Behcet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):i51–i53
3.
Duzgun N, Ayaslioglu E, Tutkak H, Aydintug OT (2005) Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet’s disease. Rheumatol Int 25:1–5PubMedCrossRef
4.
Leibowitz D, Planer D, Chajek-Shaul T (2007) Echocardiographic manifestations of Adamantiades-Behcet’s disease. Eur J Echocardiogr 8:457–462PubMedCrossRef
5.
Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, Ueda A, Nakamura S, Ohno S, Ishigatsubo Y (2003) Cytokine production profile in patients with Behcet’s disease treated with infliximab. Cytokine 24:210–218PubMedCrossRef
6.
Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP (2003) Mapping the HLA association in Behcet’s disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum 48:807–813PubMedCrossRef
7.
Kamoun M, Chelbi H, Houman MH, Lacheb J, Hamzaoui K (2007) Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet’s disease. Hum Immunol 68:201–205PubMedCrossRef
8.
Sugita S, Yamada Y, Kaneko S, Horie S, Mochizuki M (2011) Induction of regulatory T cells by infliximab in Behcet’s disease. Invest Ophthalmol Vis Sci 52:476–484PubMedCrossRef
9.
Lee SW, Lee SY, Kim KN, Jung JK, Chung WT (2010) Adalimumab treatment for life threatening pulmonary artery aneurysm in Behcet disease: a case report. Clin Rheumatol 29:91–93PubMedCrossRef
10.
Baki K, Villiger PM, Jenni D, Meyer T, Beer JH (2006) Behcet’s disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis 65:1531–1532PubMedCentralPubMedCrossRef
11.
Adler S, Baumgartner I, Villiger PM (2012) Behcet ‘s disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res 64:607–611CrossRef
12.
Tolosa-Vilella C, Capela CA, Monteagudo-Jiménez M, Marí–Alfonso B (2011) Infliximab for life-threatening pulmonary artery aneurysms in Behcet ‘s disease a case report. Clin Exp Rheumatol 29(Suppl 67):S94–S95PubMed
13.
Lee I, Park S, Hwang I, Kim MJ, Nah SS, Yoo B, Song JK (2008) Cardiac Behcet disease presenting as aortic valvulitis/aortitis or right heart inflammatory mass: a clinicopathologic study of 12 cases. Am J Surg Pathol 32:390–398PubMedCrossRef
14.
Olivieri I, Leccese P, D’Angelo S, Padula A, Nigro A, Palazzi C, Coniglio G, Latanza L (2011) Efficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 29(Suppl 67):S54–S57PubMed
15.
Leccese P, Latanza L, D’Angelo S, Padula A, Olivieri I (2011) Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet’s disease to infliximab. Clin Exp Rheumatol 29(Suppl 67):S93PubMed
16.
Leccese P, D’Angelo S, Angela P, Coniglio G, Olivieri I (2010) Switching to adalimumab is effective in a case of neuro-Behcet’s disease refractory to infliximab. Clin Exp Rheumatol 28(Suppl 60):S102PubMed
17.
Atzeni F, Leccese P, D’Angelo S, Sarzi-Puttini P, Olivieri I (2010) Successful treatment of leg ulcers in Behçet’s disease using adalimumab plus methotrexate after the failure of infliximab. Clin Exp Rheumatol 28(Suppl 60):S94PubMed
18.
Olivieri I, D’Angelo S, Padula A, Leccese P, Mennillo GA (2009) Successful treatment of recalcitrant genital ulcers of Behcet’s disease with adalimumab after failure of infliximab and etanercept. Clin Exp Rheumatol 27(Suppl 53):S112PubMed
19.
Neri P, Zucchi M, Allegri P, Lettieri M, Mariotti C, Giovannini A (2011) Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol 31:165–173PubMedCrossRef
Metadata
Title
Efficacy of adalimumab therapy for life-threatening pulmonary vasculitis in Behçet’s disease
Authors
Suhail Aamar
Hagit Peleg
David Leibowitz
Tova Chajek-Shaul
Nurith Hiller
Samuel N. Heyman
Publication date
01-06-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 6/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2693-4

Other articles of this Issue 6/2014

Rheumatology International 6/2014 Go to the issue

Original Article

Evaluating the reliability of Persian version of ankylosing spondylitis quality of life (ASQoL) questionnaire and related clinical and demographic parameters in patients with ankylosing spondylitis

Letter to the Editor

The beneficial effect of leflunomide on systemic lupus erythematosus: the role of Tregs repopulation?

Short Communication

Short-term improvement following dry needle stimulation of tender points in fibromyalgia

Original Article

The concomitant use of meloxicam and methotrexate does not clearly increase the risk of silent kidney and liver damages in patients with rheumatoid arthritis

Letter to the Editor

Lower lifetime prevalence of atopy in rheumatoid arthritis

Short Communication

The clinical profile of Kawasaki disease of children from three Polish centers: a retrospective study

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits